Dr. Reddy’s Laboratories Gets EIR From U.S. FDA For Visakhapatnam Units
People chat in the lobby of Innovation Plaza building, on Dr. Reddy’s Laboratories Ltd. campus in Hyderabad. (Photographer: Prashanth Vishwanathan/Bloomberg)

Dr. Reddy’s Laboratories Gets EIR From U.S. FDA For Visakhapatnam Units

Bookmark

Dr. Reddys Laboratories Ltd. on Thursday said it has received establishment inspection report from the U.S. health regulator for its Visakhapatnam facility in Andhra Pradesh.

The company has received EIR from the United States Food and Drug Administration for the inspection conducted at the formulations manufacturing plants at Duvvada, Visakhapatnam, Dr. Reddy's Laboratories said in a regulatory filing.

The inspection of the two facilities were completed by the U.S. FDA on June 21 this year, it added.

"We have now received an EIR from the U.S. FDA, indicating closure of this audit," the company said.

The U.S. FDA gives EIR on closure of inspection of an establishment that is the subject of an U.S. FDA or U.S. FDA-contracted inspection.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.